ClinicalTrials.gg
RecruitingNCT03737786SEACOASTUpdated Dec 26, 2025

SEACOAST 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke

An interventional study of Tight control of end-tidal CO2 levels in Acute Stroke, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2025-12-26.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's title name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Planned enrollment
154th of 364
90 · median 65
Started
2019
with 24 others
No phase
183 of 480
51 open now
Primary completion
2026-06
later than 23 of 144 live
Registered
225th of 480
by date
Lead sponsor
9 of 480
University of California, Los Angeles

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 154th largest by planned enrollment of the 364 interventional ones that give a count, is one of 25 that started in 2019, is one of 183 with no phase, reaches primary completion later than 23 of the 144 other live ones, and was the 225th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

SEACOAST 1 is a prospective, randomized, blinded endpoint trial comparing collateral vigor and clinical outcomes, with different forms of GA in patients with acute ischemic stroke due to anterior circulation large vessel occlusion (LVO) undergoing mechanical thrombectomy. The study compares GA with normocarbia (GAN) versus GA with mild hypercarbia (GAH), with a primary outcome of collateral robustness at measured at catheter angiography and clinical efficacy as secondary outcome. It is anticipated that the SEACOAST 1 will be followed by a larger, pivotal trial, SEACOAST 2, with primary clinical endpoints, in which the best method of GA identified in SEACOAST 1 is compared with the alternative strategy of anesthesia care (MAC) with minimal or no sedation. The current study focuses uppn SEACOAST 1, which is to be conducted in University of California, Los Angeles Ronald Reagan Medical Center and Santa Monica Medical Center. All acute stroke patients who arrive to one of these two stroke centers and are deemed eligible for thrombectomy will be considered for the proposed study. Physician-investigators will determine study eligibility. Informed consent to participate in the study will be obtained from legally authorized representatives or competent patients. For non-competent patients without on-scene legally authorize representatives, the consent process will utilize enrollment in emergency circumstances with exemption of informed consent (EFIC).

Read the detailed description

Study design:

SEACOAST 1 is a prospective, randomized, blinded endpoint trial comparing collateral vigor and clinical outcomes, focusing on two distinct sedation strategies:

  1. General anesthesia with mild hypercarbia (GAH) during the sedation up until full revascularization versus
  2. General anesthesia with normocarbia (GAN) during the sedation up until full revascularization

Neuroanesthesia protocol, focused on maintenance of baseline BP, avoidance of hypotension during induction, and targeted partial pressure of carbon monoxide (PCO2) levels (normocarbia or mild hypercarbia):

  • Anesthesia must not delay target initiation of procedure (groin puncture) of 90 min from ED arrival
  • Standard American Society of Anesthesiologists (ASA) monitoring: 5 lead ECG, end-tidal CO2 (ETCO2), Pulse oximeter, BP monitor, Body temperature per esophageal probe, ET gas analyser
  • Neuromuscular block (NMB) monitor for depth of neuromuscular blockade
  • Arterial line placement is encouraged if it can be inserted within 5 min. Otherwise noninvasive BP per cuff. If arterial line has not been placed prior to induction monitor noninvasive blood pressure (NIBP) every 1 min per cuff until arterial line becomes available.
  • BP goals - keep at baseline with goal of no more than 10% drop (last recorded BP prior to induction) and cannot exceed 185/105 if patients received intravenous tissue plasminogen activator (IV TPA).

    *BP can be lowered to desired goal only after revascularization as deemed necessary by the neurointerventional physician

  • Induction with propofol or etomidate and rocuronium 1.2 mg/kg or succinylcholine
  • Short acting vasoactive drugs (Phenylephrine, Ephedrine, Esmolol, Clevidipine) should be readily available to maintain BP in the predefined range throughout procedure. Phenylephrine drip recommended to maintain BP
  • Anesthesia maintenance with volatile anesthetic and fentanyl; doses to be titrated to BP per anesthesiologist
  • Qualitative end-tidal CO2 (ETCO2) measurement
  • Immediately upon groin puncture interventionalist will provide blood gas sample to test arterial C02

A. Normocarbia arm:

Controlled ventilation with PCO2 levels 40 (±5%)

B. Mild hypercarbia arm:

Controlled ventilation with PCO2 levels 50 (±5%)

  • Normalize PCO2 levels to 40 (±5%) immediately after adequate revascularization (TICI 2B)
  • Baseline arterial blood gas values for correlation/correction with PCO2 level detected on ETCO2 measurements
  • Mandatory extubation attempt within 60 minutes after procedure completion. Reasons for failed extubation should be documented
03

Conditions studied

  • Acute Stroke

Browse trials for

Keywords

  • large vessel occlusion
  • anesthesia
  • thrombectomy
  • acute ischemic stroke
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 90 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Age ≥18
  2. NIHSS ≥ 6 within 0-16h or NIHSS ≥ 10 within 16-24h
  3. Anterior circulation large vessel occlusion (ICA, M1, M2)
  4. ASPECTS score ≥ 6 within the first 6h, or DEFUSE trial imaging criteria within 6-16h; or DAWN trial clinical/imaging mismatch criteria within 16-24h
  5. Premorbid modified Rankin Scale (mRS) 0-2
  6. Patient deemed candidate for mechanical thrombectomy with anticipated groin puncture within 24 hours of last known well and within 90 min of ED arrival

Clinical Exclusion Criteria:

  1. Intubation in ED prior to anesthesiologist evaluation, or intubation for any other medical reason other than planned thrombectomy
  2. Rapid neurological improvement, suggestive of revascularization
  3. Known serious sensitivity to radiographic contrast agents.
  4. Current participation in another drug or device treatment study.
  5. Renal Failure as defined by a serum creatinine > 2.0 mg/dl (or 176.8 μmol/l) or [GFR] \< 30.
  6. Subject who requires hemodialysis or peritoneal dialysis, or who have a to an angiogram for whatever reason.
  7. of less than 90 days.
  8. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal
  9. Subject with a co-morbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow up assessments.
  10. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day.
  11. Septic or cardiogenic shock with severe life-threatening hypotension

Imaging Exclusion Criteria:

  1. Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of acute intracranial hemorrhage on presentation.
  2. CT or MRI evidence of mass effect or intracranial tumor (except small meningioma).
  3. CT showing hypodensity or MRI showing hyperintensity involving greater than 1/3 of the middle cerebral artery (MCA) territory (or in other territories, >100 cc of tissue) on presentation.
  4. Baseline non contrast CT or DWI MRI evidence of a moderate/large core defined as extensive early ischemic changes of Alberta Stroke Program Early CT score (ASPECTS) \< 6
  5. CT or MRI evidence that ischemia is not in anterior circulation distribution.
  6. Imaging evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target lesion, moderate/large infarct with poor collateral circulation, etc.).

Anesthesia exclusion criteria (relative):

  1. History of Malignant Hyperthermia
  2. History of allergic reaction/anaphylaxis to anesthetic drugs
  3. Inability to tolerate supine position (severe CHF)
  4. Chronic O2 dependence or any other known pulmonary condition that might lead to difficult extubation and prolonged mechanical ventilation including known pulmonary hypertension
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    GA with mild hypercarbia (GAH)

    Controlled ventilation with target end-tidal CO2 levels 50 (±5%)

    Other: Tight control of end-tidal CO2 levels

  • Active comparator
    GA with normocarbia (GAN)

    Controlled ventilation with target end-tidal CO2 levels 40 (±5%)

    Other: Tight control of end-tidal CO2 levels

Interventions

  • OtherTight control of end-tidal CO2 levels

    The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation

07

What researchers measure

Primary outcomes

  1. Modified Angiographic collateral circulation assessed by blinded core lab

    Modified American Society of Interventional and Therapeutic Neuroradiology (ASITN) grading scale is an ordinal 0-4 scale for angiographic collateral assessment. It runs from 0 (no collaterals) to 4 (excellent collaterals) as follows: 0: No visible collaterals to the ischemic site; 1: Slow collaterals to the periphery of the ischemic site with persistence of some defect; 2 (-): rapid collaterals to the periphery of the ischemic site with collateral filling in \<50% of the territory; 2 (+): rapid collaterals to the periphery of the ischemic site with collateral filling \> 50% of the territory; 3: Collaterals with slow but complete angiographic blood flow of the ischemic bed by the venous phase; 4: Complete and rapid collateral blood flow to the vascular bed in the entire ischemic territory by retrograde perfusion.

    Time frame: Immediately prior to revascularization

Secondary outcomes

  1. infarct growth assessed by blinded core lab

    Infarct growth will be determined by the difference in volume (cc) between baseline and post revascularization (24-72h) infarct volume. For patients assessed with MRI at the time of arrival to emergency department (ED), baseline infarct size will be determined on diffusion weighted imaging (DWI) or apparent diffusion coefficient (ADC) imaging. Final infarct size measurement will performed using a T2 fluid attenuated inversion recovery sequence with additional reference to the DWI or ADC imaging at 24-72h after intervention. For patients assessed with CT at the time of ED arrival, baseline and final (24-72h) core infarct will be determined by RAPID perfusion imaging software.

    Time frame: From the first brain imaging upon arrival to emergency department (ED) up to 72 hours after intervention

  2. modified Rankin Scale assessed by a blinded investigator

    The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death: 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead

    Time frame: 90 days after intervention

  3. safety endpoints (defined as any parenchymal hematoma (PH), subarachnoid hemorrhage (SAH), or intraventricular (IVH) associated with death, or worsening of National Institute of Health Stroke Scale score (NIHSS) by 4 or more within 24 hours)

    defined as any parenchymal hematoma (PH), subarachnoid hemorrhage (SAH), or intraventricular (IVH) associated with death, or worsening of National Institute of Health Stroke Scale score (NIHSS) by 4 or more within 24 hours

    Time frame: from the end of thrombectoy procedure up to 24 hours after intervention

08

Study locations

1 of 1 sites recruiting
  • UCLA Stroke Center
    Los Angeles, California 90095, United States
    Recruiting
    • Radoslav Raychev, MD · Contactrraychev@mednet.ucla.edu · 310-794-6379
    • Gilda Avila · ContactGAvila@mednet.ucla.edu · 310-825-1805
    • Radoslav Raychev, MD · Principal investigator
    • Jeffrey Saver, MD · Sub investigator
    • Natalie Moreland, MD · Sub investigator
    • Reza Jahan, MD · Sub investigator
09

References and documents

Publications

  • Tosello R, Riera R, Tosello G, Clezar CN, Amorim JE, Vasconcelos V, Joao BB, Flumignan RL. Type of anaesthesia for acute ischaemic stroke endovascular treatment. Cochrane Database Syst Rev. 2022 Jul 20;7(7):CD013690. doi: 10.1002/14651858.CD013690.pub2. PubMed 35857365 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Jun 2026, 79 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 79 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2018
First posted
Nov 13, 2018
StartActual
Nov 28, 2019
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03737786
Responsible party
Radoslav Raychev (Assistant Clinical Professor, University of California, Los Angeles) — Principal investigator
First posted
Nov 13, 2018
Start date
Nov 28, 2019
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 26, 2025

Study contacts

Radoslav Raychev, MD
Contact
rraychev@mednet.ucla.edu
310-794-6379
Gilda Avila
Contact
GAvila@mednet.ucla.edu
310-825-1806
Radoslav Raychev, MD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion